Jorge Andres  Cedron net worth and biography

Jorge Cedron Biography and Net Worth

Insider of Orthofix Medical

Andres Cedron serves as Chief Legal Officer at Orthofix. He brings nearly 20 years of executive legal experience to his role.

Most recently, he served as Vice President and Corporate Secretary at Stryker Corporation, a $20B+ global medical device company. In his corporate officer position, Mr. Cedron oversaw corporate governance, SEC compliance, mergers and acquisitions, and ESG matters. Prior to that, Mr. Cedron held leadership roles as Chief Legal Counsel for Stryker’s $10B+ MedSurg and Neurotechnology Group from 2018 to 2022, as well as the company’s EMEA and Latin America regions from 2015 to 2018. He has extensive expertise in regulatory and compliance frameworks, anti-corruption programs, litigation management and commercial legal strategies in the medical device industry.

Mr. Cedron started his career as a corporate attorney at law firms in New York and Miami. He holds a J.D. from Columbia Law School and a B.A. from Colorado College. He is fluent in English, Spanish and Portuguese.

What is Jorge Andres Cedron's net worth?

The estimated net worth of Jorge Andres Cedron is at least $482.80 thousand as of April 16th, 2025. Cedron owns 42,500 shares of Orthofix Medical stock worth more than $482,800 as of July 11th. This net worth evaluation does not reflect any other assets that Cedron may own. Learn More about Jorge Andres Cedron's net worth.

How do I contact Jorge Andres Cedron?

The corporate mailing address for Cedron and other Orthofix Medical executives is 3451 Plano Parkway, Lewisville TX, 75056. Orthofix Medical can also be reached via phone at (214) 937-2000 and via email at [email protected]. Learn More on Jorge Andres Cedron's contact information.

Has Jorge Andres Cedron been buying or selling shares of Orthofix Medical?

Jorge Andres Cedron has not been actively trading shares of Orthofix Medical during the last quarter. Most recently, Jorge Andres Cedron sold 3,816 shares of the business's stock in a transaction on Wednesday, April 16th. The shares were sold at an average price of $13.31, for a transaction totalling $50,790.96. Following the completion of the sale, the insider now directly owns 42,500 shares of the company's stock, valued at $565,675. Learn More on Jorge Andres Cedron's trading history.

Who are Orthofix Medical's active insiders?

Orthofix Medical's insider roster includes Julie Andrews (CFO), Catherine Burzik (Director), Massimo Calafiore (CEO), Jorge Cedron (Insider), Rice Doug (CFO), Kimberley Elting (Insider), Geoffrey Gillespie (CAO), James Hinrichs (Director), Aviva McPherron ( President of Global Operations and Quality), Michael Paolucci (Director), Jon Serbousek (CEO), and Lucas Vitale (Insider). Learn More on Orthofix Medical's active insiders.

Are insiders buying or selling shares of Orthofix Medical?

In the last year, Orthofix Medical insiders bought shares 4 times. They purchased a total of 113,500 shares worth more than $1,394,857.50. In the last year, insiders at the medical device company sold shares 13 times. They sold a total of 37,645 shares worth more than $604,129.10. The most recent insider tranaction occured on July, 2nd when Major Shareholder Engine Capital Management, Lp bought 1,250 shares worth more than $13,887.50. Insiders at Orthofix Medical own 1.3% of the company. Learn More about insider trades at Orthofix Medical.

Information on this page was last updated on 7/2/2025.

Jorge Andres Cedron Insider Trading History at Orthofix Medical

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/16/2025Sell3,816$13.31$50,790.9642,500View SEC Filing Icon  
See Full Table

Jorge Andres Cedron Buying and Selling Activity at Orthofix Medical

This chart shows Jorge Andres Cedron's buying and selling at Orthofix Medical by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Orthofix Medical Company Overview

Orthofix Medical logo
Orthofix Medical Inc. operates as a spine and orthopedics company in the United States, Italy, Germany, the United Kingdom, France, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures and distributes bone growth stimulator devices for enhance of bone fusion, including adjunctive and noninvasive treatment of cervical and lumbar spine, as well as a therapeutic treatment for non-spine; designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and offers biological products, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers, and tissue forms, which allow physicians to treat various spinal and orthopedic conditions. This segment also designs, develops, and markets a portfolio of navigation technologies, including tracked surgical tools, intelligent software, and imaging equipment based on machine-vision and optical innovations. The Global Orthopedics segment offers products and solutions that allow physicians to treat various orthopedic conditions related to limb reconstruction and deformity correction unrelated to the spine. This segment designs, develops, and markets external and internal fixation orthopedic products that are coupled with enabling digital technologies to serve the complete patient treatment pathway. It sells its products through distributors and sales representatives to hospitals, healthcare organizations, and healthcare providers. The company was formerly known as Orthofix International N.V. and changed its name to Orthofix Medical Inc. in 2018. Orthofix Medical Inc. was founded in 1980 and is headquartered in Lewisville, Texas.
Read More

Today's Range

Now: $11.36
Low: $11.19
High: $11.60

50 Day Range

MA: $11.39
Low: $10.34
High: $13.79

2 Week Range

Now: $11.36
Low: $10.24
High: $20.73

Volume

315,711 shs

Average Volume

290,318 shs

Market Capitalization

$445.08 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.8